Studies have shown pimozide's effectiveness in inhibiting epithelial‐mesenchymal transition and migration invasion in prostate cancer and hepatocellular carcinoma by downregulating N‐cadherin expression and upregulating E‐cadherin expression.47, 48. The gene discussed is CDH2; the disease is prostate carcinoma.